重组白细胞介素-2联合或不联合重组干扰素- β治疗非霍奇金淋巴瘤的II期研究。癌症和白血病B组的研究。

D B Duggan, M T Santarelli, K Zamkoff, S Lichtman, J Ellerton, R Cooper, B Poiesz, J R Anderson, C D Bloomfield, B A Peterson
{"title":"重组白细胞介素-2联合或不联合重组干扰素- β治疗非霍奇金淋巴瘤的II期研究。癌症和白血病B组的研究。","authors":"D B Duggan, M T Santarelli, K Zamkoff, S Lichtman, J Ellerton, R Cooper, B Poiesz, J R Anderson, C D Bloomfield, B A Peterson","doi":"10.1097/00002371-199208000-00006","DOIUrl":null,"url":null,"abstract":"Interleukin-2 (IL-2) and interferon-beta (IFN-beta) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-beta is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-beta in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-beta is not effective therapy for NHL in the doses and schedule used in this study.","PeriodicalId":77209,"journal":{"name":"Journal of immunotherapy : official journal of the Society for Biological Therapy","volume":"12 2","pages":"115-22"},"PeriodicalIF":0.0000,"publicationDate":"1992-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00002371-199208000-00006","citationCount":"23","resultStr":"{\"title\":\"A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.\",\"authors\":\"D B Duggan, M T Santarelli, K Zamkoff, S Lichtman, J Ellerton, R Cooper, B Poiesz, J R Anderson, C D Bloomfield, B A Peterson\",\"doi\":\"10.1097/00002371-199208000-00006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Interleukin-2 (IL-2) and interferon-beta (IFN-beta) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-beta is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-beta in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-beta is not effective therapy for NHL in the doses and schedule used in this study.\",\"PeriodicalId\":77209,\"journal\":{\"name\":\"Journal of immunotherapy : official journal of the Society for Biological Therapy\",\"volume\":\"12 2\",\"pages\":\"115-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/00002371-199208000-00006\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of immunotherapy : official journal of the Society for Biological Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/00002371-199208000-00006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunotherapy : official journal of the Society for Biological Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00002371-199208000-00006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 23

摘要

白细胞介素-2 (IL-2)和干扰素- β (ifn - β)已被证明具有抗淋巴细胞恶性肿瘤的活性,可能是由淋巴因子激活的杀伤细胞(LAK)和自然杀伤细胞(NK)活性的增强介导的。有体外和体内证据表明,IL-2和ifn - β联合使用具有协同作用。癌症和白血病B组(CALGB)在49例复发或难治性非霍奇金淋巴瘤(NHL)患者中进行了IL-2联合或不联合ifn - β的随机II期试验。总体毒性很严重,17例患者出现危及生命的毒性。3名患者因治疗而死亡。7例患者(17%)出现缓解。在毒性特征、反应率或体内NK和LAK活性的调节方面,治疗组之间没有显著差异。我们得出结论,在本研究中使用的剂量和方案中,IL-2与ifn - β或不含ifn - β都不是NHL的有效治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
Interleukin-2 (IL-2) and interferon-beta (IFN-beta) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-beta is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-beta in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-beta is not effective therapy for NHL in the doses and schedule used in this study.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信